Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;10(2):76-85.
doi: 10.1007/s11899-015-0251-8.

Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies

Partow Kebriaei  1 , Michelle Limei Poon
Affiliations
Review

Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies

Partow Kebriaei et al. Curr Hematol Malig Rep. 2015 Jun.

Abstract

The prognosis of acute lymphoblastic leukemia (ALL) in adults remains poor, and novel treatment options are needed to improve outcomes. Immunotherapeutic strategies have been a recent focus in this area, targeting specific surface antigens on the ALL blast cells. Our review concentrates on four major class of antibody therapies, namely, (1) naked and unconjugated antibodies, (2) immunoconjugates and immunotoxins, (3) bi-specific T cell engaging (BiTE) therapy, and (4) chimeric antigen receptor (CAR) expressing T cells. We review preclinical and clinical data, and update on the latest advances in this exciting field, and suggest how these therapies can be incorporated into the treatment algorithm for ALL.

PubMed Disclaimer

References

    1. Lancet Oncol. 2012 Apr;13(4):403-11 - PubMed
    1. Haematologica. 2010 Feb;95(2):324-8 - PubMed
    1. Br J Haematol. 2011 Aug;154(4):471-6 - PubMed
    1. Br J Haematol. 2014 May;165(4):504-9 - PubMed
    1. J Clin Oncol. 2004 Oct 15;22(20):4075-86 - PubMed

MeSH terms

LinkOut - more resources